June 5-7, 2018: UAS Labs with Full Docket of Presentations at Probiota Americas
UAS Labs is excited to have a very active presence in this year’s Probiota Americas! See below for opportunities to gain insights from our probiotic experts or visit us at our booth!
Presentation – IPA Committee Update
When: Wednesday, June 6th at 9:35 AM
Initial Speaker: President & CEO of UAS Labs and Vice President of the IPA, Kevin Mehring
Description: Members from the IPA (International Probiotics Association) will provide an update on their regulatory progress and other activities
Roundtable Lunch – Probiotic Benefits Outside the Gut
When: Wednesday, June 6th at 1:00 PM
Host: President & CEO of UAS Labs, Kevin Mehring
Description: Probiotics are typically associated with their ability to support two primary health areas: digestive and immune. However, waves of research studies are suggesting that the influence of probiotics extends far beyond the gut. UAS Labs is the provider of probiotic strains known for cholesterol support, children’s respiratory and skin health and, most recently, weight management. We invite you to join us as we discuss probiotic benefits outside the gut, the science to support them and the communication needed to make these products successful.
Presentation – Probiotics and Heart Health; the Emerging Role of Gut Microbes in Cardiovascular Health
When: Thursday, June 7th at 9:35 AM
Speaker: Chief Scientific Officer of UAS Labs, Dr. Gregory Leyer, PhD
Description: Studies have shown that alterations to the gut microbiome affect levels of bile acid metabolism, and that a dysbiotic microbiome may be associated with metabolic disease. A disrupted gut microbiome, including a reduction of bile salt hydrolase active bacteria, can significantly impair the metabolism of bile acids and may result in disrupted cholesterol and glucose homeostasis. Currently, there is significant potential for the development of probiotic treatments that impact bile acid metabolism in concert with the microbiome field. We can now demonstrate that supplementing the human gut with bile salt hydrolase (BSH)-active probiotic Lactobacillus reuteri LRC can bring about significant improvements in lipid profile and markers of inflammation. Gregory reveals the science behind this discovery, the development of this unique probiotic, the results of randomized controlled trials and future expectations.